Literature DB >> 35974471

Safe implementation of transoral incisionless fundoplication as a new technique in a tertiary care center.

Shivanand Bomman1, Sofya Malashanka1, Adil Ghafoor1, David J Sanders1, Shayan Irani1, Richard A Kozarek1, Andrew Ross1, Michal Hubka1, Rajesh Krishnamoorthi1.   

Abstract

BACKGROUND/AIMS: Transoral incisionless fundoplication (TIF) is an accepted anatomic treatment for gastroesophageal reflux disease in selected patients. In this report, we analyze our institution's programmatic allocation of resources during the safe implementation of TIF as a new procedure.
METHODS: A retrospective analysis of all patients who underwent TIF from January 2020 to February 2021 at our institution was performed. The process of initially allocating the operating room (OR) with overnight admission and postoperative esophagram for added safety, and subsequently transitioning TIF to the endoscopy suite (ES) as an outpatient procedure was described. Patient safety and outcomes were evaluated during transition.
RESULTS: Thirty patients who underwent TIF were identified. The mean age was 51.2±16.0 years. TIF was performed in an OR in nine patients (30%) and 21 (70%) in the ES. All the OR patients were admitted overnight and had routine EG. In contrast, four (19%) from the ES group required clinically-indicated admission and three (14.2%) required esophagram. The mean procedure duration was significantly lower in the ES group (65.7 min vs. 84 min, p=0.02).
CONCLUSION: A stepwise, resource-efficient process was described that allowed safe initiation of TIF as a new technique and its effective transition to a fully outpatient procedure.

Entities:  

Keywords:  Gastroesophageal reflux disease; Health resources; Implementation; Transoral incisionless fundoplication

Year:  2022        PMID: 35974471      PMCID: PMC9539295          DOI: 10.5946/ce.2022.003

Source DB:  PubMed          Journal:  Clin Endosc        ISSN: 2234-2400


  14 in total

1.  Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study.

Authors:  D Keszthelyi; S V Jansen; G A Schouten; S de Kort; B Scholtes; L G J B Engels; A A M Masclee
Journal:  Aliment Pharmacol Ther       Date:  2010-09-13       Impact factor: 8.171

Review 2.  What is left of the endoscopic antireflux devices?

Authors:  Syed-Mohammed Jafri; Gaurav Arora; George Triadafilopoulos
Journal:  Curr Opin Gastroenterol       Date:  2009-07       Impact factor: 3.287

Review 3.  Efficacy of Laparoscopic Nissen Fundoplication vs Transoral Incisionless Fundoplication or Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Network Meta-analysis.

Authors:  Joel E Richter; Ambuj Kumar; Seth Lipka; Branko Miladinovic; Vic Velanovich
Journal:  Gastroenterology       Date:  2018-01-03       Impact factor: 22.682

Review 4.  Gastroesophageal Reflux Disease: A Review.

Authors:  John Maret-Ouda; Sheraz R Markar; Jesper Lagergren
Journal:  JAMA       Date:  2020-12-22       Impact factor: 56.272

Review 5.  Transoral Incisionless Fundoplication.

Authors:  Kenneth J Chang; Reginald Bell
Journal:  Gastrointest Endosc Clin N Am       Date:  2020-02-13

Review 6.  Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018.

Authors:  Anne F Peery; Seth D Crockett; Caitlin C Murphy; Jennifer L Lund; Evan S Dellon; J Lucas Williams; Elizabeth T Jensen; Nicholas J Shaheen; Alfred S Barritt; Sarah R Lieber; Bharati Kochar; Edward L Barnes; Y Claire Fan; Virginia Pate; Joseph Galanko; Todd H Baron; Robert S Sandler
Journal:  Gastroenterology       Date:  2018-10-10       Impact factor: 22.682

7.  Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study.

Authors:  Michael Camilleri; Dominique Dubois; Bernard Coulie; Michael Jones; Peter J Kahrilas; Anne M Rentz; Amnon Sonnenberg; Vincenzo Stanghellini; Walter F Stewart; Jan Tack; Nicholas J Talley; William Whitehead; Dennis A Revicki
Journal:  Clin Gastroenterol Hepatol       Date:  2005-06       Impact factor: 11.382

8.  Transoral incisionless fundoplication: is it as safe and efficacious as a Nissen or Toupet fundoplication?

Authors:  Paul Toomey; Anthony Teta; Krishen Patel; Sharona Ross; Prashant Sukharamwala; Alexander S Rosemurgy
Journal:  Am Surg       Date:  2014-09       Impact factor: 0.688

9.  The TEMPO Trial at 5 Years: Transoral Fundoplication (TIF 2.0) Is Safe, Durable, and Cost-effective.

Authors:  Karim S Trad; William E Barnes; Elizabeth R Prevou; Gilbert Simoni; Jennifer A Steffen; Ahmad B Shughoury; Mamoon Raza; Jeffrey A Heise; Mark A Fox; Peter G Mavrelis
Journal:  Surg Innov       Date:  2018-02-06       Impact factor: 2.058

Review 10.  The evolution of TIF: transoral incisionless fundoplication.

Authors:  Glenn M Ihde
Journal:  Therap Adv Gastroenterol       Date:  2020-05-21       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.